Australia: Pfizer case shows protecting your own position isn't anti-competitive

Last Updated: 9 March 2015

Commercial strategies and practices used by Pfizer to counter the expected loss of revenue caused by the expiry of its patent over Lipitor, its bestselling cholesterol drug, were neither misuses of market power nor exclusive dealing and did not contravene Australian competition laws (Australian Competition and Consumer Commission v Pfizer Australia Pty Ltd [2015] FCA 113).

In yet another high-profile loss for the ACCC, the Court held that steps taken by Pfizer in offering stock and making bundled offers were carried out for a purpose of defending Pfizer's sales in response to strong competition from generics. In effect, the Court found Pfizer's strategies were legitimate forms of competition in the face of sustained attack by generics.

Pfizer's commercial strategy to deal with the patent expiry

Pfizer needed to manage the erosion of revenue that would come from the expiry of its patent over the molecule atorvastatin, which it sold as Lipitor, and the subsequent increase in competition from generics, so it took a number of steps:

  • it announced it would no longer supply prescription pharmaceuticals through wholesalers; henceforth it would sell directly to community pharmacies (the "Direct-to-Pharmacy Model");
  • it established an Accrual Funds Scheme – a percentage of the price of purchases of Pfizer pharmaceutical products was credited to an account created for each pharmacy to be rebated on terms which would be announced at a later date; and
  • it offered terms upon which it would supply Lipitor and its own generic Atorvastatin Pfizer to all, or virtually all, community pharmacies. These terms tied the rebates that were available from the accrual fund to the quantity of Atorvastatin Pfizer that the pharmacy purchased.

The ACCC took Pfizer to the Federal Court, alleging it had contravened the Competition and Consumer Act 2010 (Cth) by:

  • using its substantial power in the market for atorvastatin for an anti-competitive purpose – to deter or prevent a person from engaging in competitive conduct in the market (section 46(1)(c)); and
  • engaging in exclusive dealing with the effect of a substantial lessening of competition (sectfion 47).

Pfizer's actions were not misuse of market power

Until late 2011, Pfizer did possess "substantial market power" in the market for atorvastatin as the sole supplier of that product. This is the requisite level of market strength for the application of section 46 and is a key threshold provision in any misuse case. The limited degree of price regulation under the PBS was not sufficient to prevent Pfizer being assessed as having substantial market power.

But section 46 requires that the conduct in question must represent a taking of advantage of substantial market power for a purpose of deterring other parties from competing.

Pfizer's declining market power

By the time Pfizer made its bundled offers to customers in January 2012, its power had already weakened. Well before Pfizer's patent expired in May 2012, other generic manufacturers planned their onslaught on the market. Pfizer's market power gradually decreased as the patent expiry date grew nearer. Pfizer maintained some degree of market power up to May 2012 because of its unique ability to exploit the marketing of Lipitor at a premium price and to package its generic in a very similar manner.

But from January 2012 Pfizer's power was not substantial, because:

  • from late 2011, a generic rival, Ranbaxy had been promoting the sale of its generic at discounts of 85% off the chemist list price and could enter the market from 19 February 2012 and pose a serious challenge;
  • a number of other generics had registered their competing products with the Australian regulatory authorities;
  • Apotex was holding discussions with key customers regarding its offers and arranging for its stock to be flown to Australia the very day the patent expired;
  • Alphapharm told customers in January 2012 it would beat Pfizer's offer and offered 12 months' worth of products;
  • Ascent was marketing to pharmacies not to succumb to a Pfizer offer;
  • Sandoz was writing to all customers advising them to seek advice on whether to accept Pfizer's offers.

Rebates not a marketing method unique to companies with substantial market power

The Court held that Pfizer was pursuing no different strategy than what was open to any other supplier. To offer a rebate doesn't involve taking advantage of market power.

Granted, it was only by reason of Pfizer's market power in January 2011 that it could announce a rebate scheme without telling pharmacies how they could recover the moneys that were accumulating for their benefit. But Pfizer was not taking advantage of market power in making the offers in January 2012.

Even if Pfizer did supply its generic below cost, the offers were made during launch phase for a relative short period of time and did not establish a "taking advantage" of market power.

Pfizer did not have anti-competitive purpose

The Court rejected a finding that Pfizer's action indicated that it had a purpose of preventing other generics from supplying the market.

Pfizer accepted that competition was inevitable from generics, and its documents referred to "blocking" generics.

The Court held that the desire to cause harm to competitors is not necessarily proof of anticompetitive purpose. Pfizer took the steps it did to avoid being "slaughtered".

Effect of Pfizer's marketing strategy

The Court noted that Pfizer rapidly lost market share in the market after the patent expiry to generics, so it was difficult to see that generics had been seriously damaged or deterred by Pfizer's actions. In other words, anti-competitive effects did not arise from Pfizer's conduct.

Exclusive dealing

The ACCC's case failed because the judge found the purpose was to maximise Pfizer's sales for its products and that was not a purpose of substantial lessening of competition. The ACCC did not allege that Pfizer's conduct had the effect of substantially lessening competition.

Impact of the Pfizer case

The judgment comes on the back of increased scrutiny worldwide, particularly in the US and EU, of commercial strategies used by pharmaceutical patent holders to delay or deter generic entry and competition.

More close to home in Australia, the ACCC has flagged competition and consumer issues in the medical and health sectors as a priority enforcement area, and the Harper Review Panel in its root and branch review of competition laws is considering calls for an effects-based test to be added to the misuse of market power provisions of the Competition and Consumer Act 2010 (Cth).

It's also the second of three high-profile cases on misuse of market power issued by the ACCC in the last three or so years. The ACCC has not succeeded in establishing contraventions of the misuse of market power provisions in the first two. The last of these cases (ACCC v Visa) is currently before the Federal Court of Australia.

The result in ACCC v Pfizer could add weight to calls by the ACCC and others for reform of the misuse of market power provisions of the Competition and Consumer Act. Critics have argued for some time that the law in this area is deficient and that the misuse of market power provisions are not an effective enforcement tool. However it is questionable whether the ACCC would have succeeded with an "effects test" law in this case of the kind it has been pushing for. The fact that the ACCC has failed again in such a case, though not for the same reasons as earlier cases, where the "taking advantage" limb of the test has been difficult to overcome, might encourage the Harper Review Panel to find that an effects-based test (in addition to the current "purpose" test) is necessary. How this plays out when the Harper Review Panel issues its final report later this month will be interesting viewing.

It is not yet known whether the ACCC will seek to appeal the decision.

Clayton Utz communications are intended to provide commentary and general information. They should not be relied upon as legal advice. Formal legal advice should be sought in particular transactions or on matters of interest arising from this bulletin. Persons listed may not be admitted in all states and territories.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.